Search clinical trials for: atorvastatin plus ezetimibe

Total 6031 results

Organon and Co

Terminated

Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

Cardiovascular Diseases | Diabetes Mellitus
Aegerion Pharmaceuticals, Inc.

Completed

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Hyperlipidemia

United States
Yonsei University

Recruiting

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

Dyslipidemias | Atherosclerotic Cardiovascular Disease

Korea, Republic of
Penza State University

Recruiting

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI (CONTRAST-2)

Quality of Life | Arterial Stiffness | Myocardial Infarction, Acute | Myocardial Strain

Russian Federation
University of Cologne
Merck Sharp & Dohme LLC

Completed

LDL Receptor Under Ezetimibe and Simvastatin

Healthy Men

Germany
Organon and Co

Completed

A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)

Type 2 Diabetes Mellitus | Hypercholesterolemia
Organon and Co
PT. Schering-Plough. Tbk Indonesia

Completed

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

Hypercholesterolemia | Coronary Arteriosclerosis
Organon and Co

Completed

Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)

Hypercholesterolemia
Organon and Co

Completed

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Familial Hypercholesterolemia
Medical University of Graz

Completed

Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk

Hypercholesterolemia

Austria
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Active, not recruiting

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY EAST)

Hypercholesterolemia

China, India, Thailand
University of Sao Paulo

Completed

Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons

Coronary Heart Disease
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
University Clinical Centre of Republic of Srpska

Recruiting

Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry (RS-ACS)

Dyslipidemias | Acute Coronary Syndrome

Bosnia and Herzegovina
Organon and Co
Merck Sharp & Dohme LLC

Completed

Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578) (ENHANCE)

Atherosclerosis | Hypercholesterolemia | Hyperlipoproteinemia Type II
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Hypercholesterolemia

France, Belgium, Austria, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Poland, Romania, Slovakia, Slovenia, Spain, Switzerland
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
University of Oxford
National Health and Medical Research Council, Australia; Merck Sharp & Dohme... and other collaborators

Completed

Study of Heart and Renal Protection (SHARP)

Kidney Disease, Chronic

United Kingdom
Organon and Co

Completed

Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

Metabolic Syndrome | Hypercholesterolemia
Organon and Co

Completed

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

Hypercholesterolemia
Organon and Co

Completed

Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Hypercholesterolemia
Hotel Dieu de France Hospital
Pfizer; Nouvelle Société Française d'Athérosclérose

Completed

The HDL Particle Protection Study (HDL PROTECT)

Dyslipidemia in Patients With Diabetes Mellitus

Lebanon
Yonsei University

Unknown

RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)

Cardiovascular Diseases | Cerebrovascular Disease | Peripheral Atherosclerotic Disease

Korea, Republic of
University of California, San Diego
Merck Sharp & Dohme LLC

Terminated

Ezetimibe in Patients Hypo-responsive to Statins

Coronary Artery Disease | High Cholesterol

United States
Merck Sharp & Dohme LLC

Completed

A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet (LOCUST)

Hyperlipidemia
Seung-Whan Lee, M.D., Ph.D.
Yuhan Corporation

Recruiting

Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)

Pre Diabetes | ASCVD

Korea, Republic of
GlaxoSmithKline

Completed

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

Hypertriglyceridemia
Yonsei University
dotter

Recruiting

Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

Coronary Artery Disease | Dyslipidemias

Korea, Republic of
NYU Langone Health

Completed

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes (CHORD)

Type 2 Diabetes

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Pfizer

Completed

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

HIV-1 Infection

United States, Puerto Rico
Yuhan Corporation

Completed

Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome

Acute Coronary Syndrome | Carotid Atherosclerotic Plaque With Inflammation

Korea, Republic of
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Hypercholesterolemia

Japan
Samsung Medical Center

Not yet recruiting

High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium (DECISION-CAL)

Metabolic Syndrome | Dyslipidemias | Coronary Artery Calcification
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Hyperlipidemia

United States, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Wilma Williams Education and Clinical Research for Endometrial Cancer Award

Completed

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

Endometrial Cancer

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Hypercholesterolemia

United States, France, Italy, Israel, United Kingdom, Austria, Canada, Norway
Organon and Co

Completed

Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)

Coronary Disease | Hypercholesterolemia
Organon and Co

Completed

An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)

Coronary Disease | Hypercholesterolemia
Federal University of São Paulo

Completed

Effect of Simvastatin and Ezetimibe on Lipid and Inflammation

Inflammation | Hypercholesterolemia | Cardiovascular Risk | Prediabetes

Brazil
Organon and Co

Completed

Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)

Coronary Disease | Hypercholesterolemia
Organon and Co

Completed

Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)

Coronary Disease | Hypercholesterolemia
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Active, not recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
Astellas Pharma Inc

Completed

Special Drug Use-Results Survey of Lipitor Tablets (ALWAYS)

Hypercholesterolemia

Japan
Bronx VA Medical Center

Completed

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Hypercholesterolemia

United States
The Catholic University of Korea
Jeil Pharmaceutical Co., Ltd.

Terminated

The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) (PIONEER)

Coronary Artery Disease | Atherosclerosis

Korea, Republic of
Korea University

Withdrawn

Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

Atherosclerosis

Korea, Republic of
Cao Yu

Recruiting

Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Therapeutic Equivalency

China
The Affiliated Hospital of Qingdao University

Completed

Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Hyperlipidemias

China

3

Subscribe